Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune problems in central nervous system cell therapy.

Roger A Barker1, Håkan Widner

  • 1Cambridge Center for Brain Repair and Department of Neurology, Cambridge CB2 6SP, United Kingdom.

Neurorx : the Journal of the American Society for Experimental Neurotherapeutics
|February 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson's disease.

BMJ open·2025
Same author

Mapping the distribution of neurotransmitters to resting-state functional connectivity in Parkinson's disease.

Brain communications·2025
Same author

The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.

Nature biotechnology·2025
Same author

Immunology of cell and gene therapy approaches for neurologic diseases.

Handbook of clinical neurology·2024
Same author

Patients accept therapy using embryonic stem cells for Parkinson's disease: a discrete choice experiment.

BMC medical ethics·2023
Same author

Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD.

Cell stem cell·2023

The brain is not an immunologically privileged site, as immune responses can occur following cell transplantation. Understanding these immune reactions is crucial for successful central nervous system (CNS) cell therapies.

Area of Science:

  • Neuroscience
  • Immunology
  • Transplantation Biology

Background:

  • The central nervous system (CNS) was once considered an immunologically privileged site, but recent findings challenge this view.
  • Cell and tissue transplantation into the mammalian brain and CNS necessitates a re-evaluation of the brain's immune status and response to grafted tissues.

Purpose of the Study:

  • To review the immunological factors involved in cell transplantation to the CNS.
  • To highlight the complexities of immune responses in the context of CNS cell therapies, especially for neurodegenerative and immune-based disorders.

Main Methods:

  • Review of existing literature on brain immunology and cell transplantation.
  • Analysis of clinical cell transplant trials for various neurological and retinal disorders.

Related Experiment Videos

  • Examination of immune reactions to different cell sources (allogeneic, xenogeneic, stem cells).

    • Main Results:

    • The brain is not absolutely immune privileged; immune responses can occur and be vigorous.
    • Cellular therapies are being explored for Parkinson's disease, Huntington's disease, multiple sclerosis, and other CNS conditions.
    • Alternative cell sources like stem cells are being investigated due to ethical and logistical issues with human fetal tissue, but they also elicit immune responses.

    Conclusions:

    • CNS immune responses are modified but can be as potent as peripheral responses.
    • Successful CNS cell transplantation requires careful consideration of the immunological environment and potential graft rejection.
    • Further research into managing immune reactions is vital for advancing cell-based therapies in the CNS.